First Manhattan’s Avidity Biosciences RNAM Stock Holding History

First Manhattan’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200	Closed	-$1.28K	–	1551
2023 Q3	$1.28K	Hold	200	–	–	﹤0.01%	1340
2023 Q2	$2.22K	Hold	200	–	–	﹤0.01%	1295
2023 Q1	$3.07K	Hold	200	–	–	﹤0.01%	1351
2022 Q4	$4.44K	Hold	200	–	–	﹤0.01%	1429
2022 Q3	$3K	Hold	200	–	–	﹤0.01%	1395
2022 Q2	$2K	Hold	200	–	–	﹤0.01%	1444
2022 Q1	$3K	Hold	200	–	–	﹤0.01%	1458
2021 Q4	$4K	Hold	200	–	–	﹤0.01%	1409
2021 Q3	$4K	Hold	200	–	–	﹤0.01%	1444
2021 Q2	$4K	Hold	200	–	–	﹤0.01%	1441
2021 Q1	$4K	Buy	+200	New	+$4.9K	﹤0.01%	1374

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

First Manhattan's RNAM Position: Q4 2023 in Review

First Manhattan sold out of Avidity Biosciences (RNAM) in Q4 2023, closing a stake of 200 shares — an estimated $1.28K sold.

First Manhattan first reported a position in RNAM in Q1 2021 and held it in 11 quarters. The position peaked at $4.44K in Q4 2022. 144 funds tracked by Wall St. Rank hold RNAM as of Q4 2023.

First Manhattan reported no remaining Avidity Biosciences position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 200 Avidity Biosciences shares in Q4 2023, an estimated $1.28K.
First Manhattan first reported a position in Avidity Biosciences in Q1 2021 and held it in 11 quarters.
First Manhattan's Avidity Biosciences position peaked at $4.44K in Q4 2022.
144 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.